Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $56.61 million. The enterprise value is $50.94 million.
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 75.35 million shares outstanding. The number of shares has increased by 33.15% in one year.
| Current Share Class | 75.35M |
| Shares Outstanding | 75.35M |
| Shares Change (YoY) | +33.15% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 16.72% |
| Float | 75.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.01 |
| Forward PS | 8.96 |
| PB Ratio | 7.21 |
| P/TBV Ratio | 8.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 1.08.
| Current Ratio | 1.03 |
| Quick Ratio | 0.91 |
| Debt / Equity | 1.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -60.36 |
Financial Efficiency
Return on equity (ROE) is -221.66% and return on invested capital (ROIC) is -90.82%.
| Return on Equity (ROE) | -221.66% |
| Return on Assets (ROA) | -67.62% |
| Return on Invested Capital (ROIC) | -90.82% |
| Return on Capital Employed (ROCE) | -610.18% |
| Revenue Per Employee | $194,902 |
| Profits Per Employee | -$989,854 |
| Employee Count | 41 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.47% in the last 52 weeks. The beta is 1.51, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -54.47% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 42.82 |
| Average Volume (20 Days) | 129,658 |
Short Selling Information
The latest short interest is 867,049, so 1.15% of the outstanding shares have been sold short.
| Short Interest | 867,049 |
| Short Previous Month | 883,413 |
| Short % of Shares Out | 1.15% |
| Short % of Float | 1.15% |
| Short Ratio (days to cover) | 4.01 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $7.99 million and -$40.58 million in losses. Loss per share was -$0.65.
| Revenue | 7.99M |
| Gross Profit | -28.30M |
| Operating Income | -41.22M |
| Pretax Income | -49.97M |
| Net Income | -40.58M |
| EBITDA | -40.29M |
| EBIT | -41.22M |
| Loss Per Share | -$0.65 |
Full Income StatementBalance Sheet
The company has $14.05 million in cash and $7.13 million in debt, giving a net cash position of $6.92 million or $0.09 per share.
| Cash & Cash Equivalents | 14.05M |
| Total Debt | 7.13M |
| Net Cash | 6.92M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 6.58M |
| Book Value Per Share | 0.11 |
| Working Capital | 433,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.72 million and capital expenditures -$161,000, giving a free cash flow of -$34.88 million.
| Operating Cash Flow | -34.72M |
| Capital Expenditures | -161,000 |
| Free Cash Flow | -34.88M |
| FCF Per Share | -$0.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -515.88% |
| Pretax Margin | -507.87% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |